Split-Release Gamma-Hydroxybutyrate for Once-Nightly Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing modified release formulations of gamma-hydroxybutyrate suffer from low bioavailability and inconvenience due to the need for multiple doses and high sodium intake, failing to approximate the pharmacokinetic profile of immediate release sodium oxybate administered twice nightly.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in 0.1 N hydrochloric acid and the other half in phosphate buffer pH 6.8, achieving bioavailability comparable to twice-nightly immediate release sodium oxybate, with a convenient once-daily administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of gamma-hydroxybutyrate are used, then the convenience of once-daily administration is improved, but the bioavailability is reduced compared to immediate release formulations
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion that rapidly dissolves to provide initial drug availability, and a modified release portion that dissolves more slowly to extend therapeutic effect. This segmentation allows the formulation to achieve both convenient once-daily administration and adequate bioavailability by combining the advantages of both release mechanisms.
2Reliability
If immediate release sodium oxybate is administered twice nightly, then the pharmacokinetic profile is optimized, but the treatment complexity and patient burden increase
Solution Approach 1:
The patent merges the immediate release and modified release mechanisms into a single combined formulation that can be administered once daily. The immediate release portion provides rapid initial availability while the modified release portion extends the effect throughout the night, effectively combining the benefits of multiple dosing into a single administration event.
3Reliability
If higher doses of gamma-hydroxybutyrate are used to compensate for low bioavailability, then the therapeutic effectiveness may be improved, but the sodium intake and side effects increase
Solution Approach 1:
The formulation changes the release rate parameter of the drug by combining immediate and modified release mechanisms. This allows the same therapeutic dose to be delivered more efficiently, reducing the need for dose escalation and thereby minimizing sodium intake and associated side effects while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides improved bioavailability and reduced side effects, allowing for a single nighttime dose that approximates the therapeutic effectiveness of twice-nightly immediate release sodium oxybate, with reduced sodium intake and minimal residual drug content.
Implementation Method 1
rapidly releases half of its dose in 0.1 N hydrochloric acid and the other half in phosphate buffer pH 6.8
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.